 - Part 2: Progression of disease following one VEGF pathway inhibitor for RCC e.g. sunitinib, pazopanib, sorafenib, bevacizumab, tivozanib, or cabozantinib inclusive of adjuvant therapy if there was documented disease progression during treatment. Patients may have received one additional line of an approved mTOR kinase inhibitor e.g. everolimus, temsirolimus. Prior exposure to investigational andor approved anticancer immune therapies is permitted. 